We hypothesize that in more than 50% of CLL cases where CD150 and CD180 are coexpressed simultaneous ligation of these receptors on malignant CLL B cells may result in inhibition of pro-survival Akt and MAPK signaling pathways. This evidence concerns the gene AKT1 and B-cell chronic lymphocytic leukemia.